出版商更正：一种阻断新型冠状病毒感染的人源单克隆抗体。
Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection.
作者信息
Wang Chunyan, Li Wentao, Drabek Dubravka, Okba Nisreen M A, van Haperen Rien, Osterhaus Albert D M E, van Kuppeveld Frank J M, Haagmans Bart L, Grosveld Frank, Bosch Berend-Jan
机构信息
Virology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.
Department of Cell Biology, Erasmus Medical Center, Rotterdam, the Netherlands.
出版信息
Nat Commun. 2020 May 14;11(1):2511. doi: 10.1038/s41467-020-16452-w.
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
摘要
本文的一个修订版本已发表，可通过本文顶部的链接获取。
相似文献
1
Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection.出版商更正：一种阻断新型冠状病毒感染的人源单克隆抗体。
Nat Commun. 2020 May 14;11(1):2511. doi: 10.1038/s41467-020-16452-w.
2
Publisher Correction: SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function.出版商更正：人ACE2转基因小鼠感染SARS-CoV-2会导致严重的肺部炎症和功能受损。
Nat Immunol. 2020 Nov;21(11):1470. doi: 10.1038/s41590-020-0794-2.
3
Publisher Correction: Blocking elevated p38 MAPK restores efferocytosis and inflammatory resolution in the elderly.出版商更正：阻断升高的p38丝裂原活化蛋白激酶可恢复老年人的噬菌作用和炎症消退。
Nat Immunol. 2020 Jun;21(6):696. doi: 10.1038/s41590-020-0686-5.
4
Author Correction: ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection.作者更正：ORF8和ORF3b抗体是新冠病毒早期和晚期感染的准确血清学标志物。
Nat Immunol. 2020 Oct;21(10):1302. doi: 10.1038/s41590-020-0788-0.
5
Author Correction: Pre-existing immunity to SARS-CoV-2: the knowns and unknowns.作者更正：对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的既往免疫力：已知与未知
Nat Rev Immunol. 2020 Oct;20(10):644. doi: 10.1038/s41577-020-00430-w.
6
Author Correction: Detection of SARS-CoV-2 in nasal swabs using MALDI-MS.作者更正：使用基质辅助激光解吸电离质谱法检测鼻拭子中的严重急性呼吸综合征冠状病毒2
Nat Biotechnol. 2020 Oct;38(10):1211. doi: 10.1038/s41587-020-0701-2.
7
Publisher Correction: Antibody engineers seek optimal drug targeting TIGIT checkpoint.出版商更正：抗体工程师寻求靶向TIGIT检查点的最佳药物。
Nat Biotechnol. 2020 Nov;38(11):1357. doi: 10.1038/s41587-020-0714-x.
8
Author Correction: A stochastic agent-based model of the SARS-CoV-2 epidemic in France.作者更正：法国SARS-CoV-2疫情的基于随机代理的模型
Nat Med. 2020 Nov;26(11):1801. doi: 10.1038/s41591-020-1129-4.
9
Publisher Correction: Asymmetric opening of HIV-1 Env bound to CD4 and a coreceptor-mimicking antibody.出版商更正：与CD4和模拟共受体抗体结合的HIV-1包膜蛋白的不对称开放。
Nat Struct Mol Biol. 2020 Jan;27(1):105. doi: 10.1038/s41594-019-0362-3.
10
Publisher Correction: Asymmetric opening of HIV-1 Env bound to CD4 and a coreceptor-mimicking antibody.出版商更正：与CD4和模拟共受体抗体结合的HIV-1 Env的不对称开放。
Nat Struct Mol Biol. 2020 Feb;27(2):222. doi: 10.1038/s41594-020-0381-0.
引用本文的文献
1
Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years.用于预防和治疗新型冠状病毒肺炎及其并发症的药物：过去两年我们所了解情况的最新进展
Front Pharmacol. 2022 Oct 10;13:987816. doi: 10.3389/fphar.2022.987816. eCollection 2022.
2
The deciphering of the immune cells and marker signature in COVID-19 pathogenesis: An update.解析 COVID-19 发病机制中的免疫细胞和标志物特征：最新进展。
J Med Virol. 2022 Nov;94(11):5128-5148. doi: 10.1002/jmv.28000. Epub 2022 Jul 23.
3
Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunity.免疫不完善的免疫系统：免疫缺陷患者的 2019 年冠状病毒病疫苗接种。
Ann Allergy Asthma Immunol. 2022 Nov;129(5):562-571.e1. doi: 10.1016/j.anai.2022.06.009. Epub 2022 Jun 16.
4
Development of superior antibodies against the S-protein of SARS-Cov-2 using macrocyclic epitopes.利用大环表位开发针对新冠病毒S蛋白的优质抗体。
Arab J Chem. 2022 Mar;15(3):103631. doi: 10.1016/j.arabjc.2021.103631. Epub 2021 Dec 10.
5
An alphavirus replicon-based vaccine expressing a stabilized Spike antigen induces protective immunity and prevents transmission of SARS-CoV-2 between cats.一种表达稳定化刺突抗原的基于甲病毒复制子的疫苗可诱导保护性免疫并预防SARS-CoV-2在猫之间的传播。
NPJ Vaccines. 2021 Oct 20;6(1):122. doi: 10.1038/s41541-021-00390-9.
6
Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and With Human Immunodeficiency Virus on Antiretroviral Therapy During the First South African Infection Wave.在南非首次感染浪潮期间，接受抗逆转录病毒治疗的艾滋病毒感染者和未感染者对严重急性呼吸综合征冠状病毒 2 的抗体反应相似。
Clin Infect Dis. 2022 Aug 24;75(1):e249-e256. doi: 10.1093/cid/ciab758.
7
Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突糖蛋白的新型中和单克隆抗体的鉴定
ACS Pharmacol Transl Sci. 2021 Jul 29;4(4):1349-1361. doi: 10.1021/acsptsci.1c00058. eCollection 2021 Aug 13.
8
The role and uses of antibodies in COVID-19 infections: a living review.抗体在新冠病毒感染中的作用及应用：动态综述
Oxf Open Immunol. 2021 Jan 28;2(1):iqab003. doi: 10.1093/oxfimm/iqab003. eCollection 2021.
9
Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection.基于强效分子特征的中和单克隆抗体有望成为抗SARS-CoV-2感染的治疗药物。
Front Mol Biosci. 2021 May 31;8:670815. doi: 10.3389/fmolb.2021.670815. eCollection 2021.
10
Precision therapeutic targets for COVID-19.针对 COVID-19 的精准治疗靶点。
Virol J. 2021 Mar 29;18(1):66. doi: 10.1186/s12985-021-01526-y.
Zotero 插件